Emergent BioSolutions Inc. (NYSE: EBS) has secured a contract modification worth $56 million to supply the ACAM2000® smallpox and monkeypox (vaccinia) vaccine to the U.S. government, with deliveries set to commence this month. This latest contract brings the total projected sales for ACAM2000® and related products to over $120 million for the year, from a diverse customer base.
ACAM2000® is a crucial vaccine licensed for active immunization against smallpox and monkeypox diseases for individuals at high risk of infection. The vaccine is administered as a single dose via a bifurcated needle, and it was initially approved by the U.S. Food and Drug Administration (FDA) in 2007 for smallpox prevention and later, in August 2024, for immunization against monkeypox.
Under Emergent’s existing 10-year contract (75A50119C00071) with the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, this contract modification further underscores the company’s commitment to supporting public health preparedness.
The ACAM2000® vaccine is also licensed for smallpox in Canada, Australia, and Singapore and is stockpiled both in the U.S. and internationally.
The press release also highlights important safety information and adverse reactions associated with the vaccine, emphasizing the need for caution in specific individuals with severe immunodeficiency.
This contract modification underscores Emergent’s ongoing collaboration with the U.S. government to prioritize preparedness support and strengthen public health efforts through its medical countermeasures portfolio.
Emergent Biosolutions Inc. has been at the forefront of delivering protective and life-saving solutions for various health threats for over 25 years, including smallpox, monkeypox, botulism, Ebola, anthrax, and opioid overdose emergencies. As a result of these announcements, the company's shares have moved 3.26% on the market, and are now trading at a price of $8.23. Check out the company's full 8-K submission here.
